Kisspeptin and Ovulation: A Gentler IVF Trigger

Fertility Peptide Biomarkers

95% Maturation

In a Phase 2 trial of 60 women at high risk for ovarian hyperstimulation syndrome, kisspeptin-54 triggered oocyte maturation in 95% of patients with no cases of OHSS.

Abbara et al., Journal of Clinical Endocrinology and Metabolism, 2015

Abbara et al., Journal of Clinical Endocrinology and Metabolism, 2015

View as image

The standard IVF protocol has a dangerous bottleneck. After days of ovarian stimulation to grow multiple follicles, clinicians must trigger the final maturation of eggs before retrieval. The traditional trigger is human chorionic gonadotropin (hCG), a hormone that mimics the natural LH surge but persists in the bloodstream for up to a week. In women with many follicles, that prolonged hCG exposure can cause ovarian hyperstimulation syndrome (OHSS), a potentially life-threatening condition involving fluid shifts, blood clots, and organ dysfunction. OHSS affects up to 5% of IVF cycles and is the single most common serious complication of assisted reproduction. For a broader view of peptide biomarkers in fertility, see the pillar article on AMH: the peptide biomarker for fertility.

Kisspeptin-54, a hypothalamic neuropeptide that sits upstream of the entire reproductive hormone cascade, has emerged as a physiologically gentler alternative. Rather than directly activating ovarian LH receptors the way hCG does, kisspeptin triggers the brain's own GnRH neurons to release a natural, self-limiting LH surge. The clinical data from Phase 2 trials at Imperial College London show that this approach matures eggs at rates comparable to hCG while producing a fraction of the OHSS risk.^[1]

How Kisspeptin Controls the Reproductive Cascade

Kisspeptin is not a reproductive hormone in the conventional sense. It is the upstream switch that turns the reproductive hormone cascade on. Kisspeptin neurons in the hypothalamus (primarily in the arcuate nucleus and the anteroventral periventricular nucleus) project directly to GnRH neurons, which are the command neurons for reproductive function.^[2] When kisspeptin binds its receptor (KISS1R, formerly GPR54) on GnRH neurons, it triggers GnRH release into the portal circulation. GnRH then stimulates the anterior pituitary to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

This positions kisspeptin at the very top of the hypothalamic-pituitary-gonadal (HPG) axis. In normal physiology, the preovulatory LH surge that triggers egg maturation and ovulation is initiated by a kisspeptin signal. The surge is self-limiting because the downstream hormones (estradiol, progesterone) feed back to modulate kisspeptin neuron activity.

Kisspeptin neurons do not operate alone. They are part of the KNDy (Kisspeptin/Neurokinin B/Dynorphin) neuron population in the arcuate nucleus, where neurokinin B provides excitatory drive and dynorphin provides inhibitory control.^[3] This three-peptide circuit generates the pulsatile GnRH secretion that maintains normal reproductive function. Understanding this circuit matters for IVF because exogenous kisspeptin plugs into the system at its natural control point rather than bypassing it.

Why hCG Causes OHSS and Kisspeptin Does Not

The pharmacological difference is straightforward. hCG has a half-life of approximately 24-36 hours and continues to stimulate ovarian LH receptors for 5-7 days after a single injection. In a hyperstimulated ovary with many follicles, this prolonged stimulation drives excessive production of vasoactive substances (primarily VEGF), which increase capillary permeability and cause fluid to leak from the vascular space into the abdomen and lungs.

Kisspeptin-54's half-life is approximately 28 minutes. It triggers a burst of endogenous GnRH, which produces an LH surge that peaks at 4-12 hours and resolves within 24 hours.^[1] This LH surge is sufficient to trigger final oocyte maturation but is too brief to sustain the prolonged ovarian stimulation that drives OHSS. The ovary gets the maturation signal it needs without the days of continued activation that cause the dangerous cascade.

Comparative data from the Imperial College London group illustrate the difference. Median ovarian volume after triggering increased 20-fold with hCG, 8-fold with GnRH agonist (the current alternative), and 5-fold with kisspeptin. Abdominal pain occurred in 69% of patients after hCG, 22% after GnRH agonist, and 12% after kisspeptin. Vomiting occurred in 8% with hCG, 4% with GnRH agonist, and 1% with kisspeptin.

This is not a marginal improvement. In the highest-risk patients (those with polycystic ovaries and many follicles), the difference between a 20-fold and a 5-fold increase in ovarian volume can be the difference between completing the IVF cycle safely and being hospitalized.

Clinical Trial Evidence

Phase 2 Dose-Finding Trial (2015)

Abbara et al. conducted a Phase 2, multi-dose, open-label, randomized clinical trial of 60 women at high risk of developing OHSS at Hammersmith Hospital's IVF unit in London. Following standard recombinant FSH/GnRH antagonist stimulation, patients received a single subcutaneous injection of kisspeptin-54 at one of four doses (3.2, 6.4, 9.6, or 12.8 nmol/kg) to trigger oocyte maturation.^[1]

Oocyte maturation (at least one mature oocyte retrieved) occurred in 95% (57/60) of women. Embryo formation occurred in 90% (54/60). The 9.6 nmol/kg dose was identified as optimal, balancing maximal maturation rates with the most favorable LH surge kinetics. No patient developed moderate or severe OHSS, which is notable given that every participant was selected specifically because she was at high risk for it.

Second-Dose Study (2017)

A follow-up Phase 2 randomized placebo-controlled trial (62 women, also high OHSS risk) tested whether a second dose of kisspeptin-54 administered 10 hours after the first could further improve oocyte maturation rates. All patients received the established 9.6 nmol/kg dose 36 hours before egg retrieval, then were randomized to either a second kisspeptin dose or saline. The second dose prolonged the LH surge and improved the proportion of mature oocytes retrieved, demonstrating that the kisspeptin approach can be refined through dosing strategy.

Jayasena 2014: Proof of Concept

The foundational proof-of-concept study, published in the Journal of Clinical Investigation, demonstrated that kisspeptin-54 could trigger egg maturation in women undergoing standard IVF. This study established the basic safety and feasibility of the approach and set the stage for the larger dose-finding and optimization trials that followed.

These trials were all conducted by the Dhillo group at Imperial College London, which remains the primary center advancing kisspeptin as an IVF trigger. Phase 3 trials and multi-center replication are the critical next steps before regulatory approval could be pursued.

Kisspeptin Beyond IVF: Reproductive and Sexual Function

Hypoactive Sexual Desire Disorder

Mills et al. (2022) conducted a randomized, double-blind, placebo-controlled crossover trial of kisspeptin-54 infusion in 32 premenopausal women with hypoactive sexual desire disorder (HSDD).^[4] Using functional MRI, they showed that kisspeptin modulated sexual brain processing: it deactivated the left inferior frontal gyrus (associated with behavioral inhibition) and activated the right postcentral and supramarginal gyrus during sexual stimuli. Participants reported increased feelings of feeling "sexy" compared to placebo, and increased posterior cingulate cortex activation correlated with reduced sexual aversion.

This builds on earlier work by Comninos et al. (2017), who showed in 29 healthy men that kisspeptin-54 infusion enhanced limbic brain activity (amygdala, cingulate, globus pallidus, posterior thalamus, putamen) specifically in response to sexual stimuli while also reducing negative mood.^[5] Together, these studies establish that kisspeptin integrates reproductive hormone signaling with sexual and emotional brain processing in both sexes. For a related approach to sexual function through a different peptide mechanism, see the article on how bremelanotide works.

PCOS and Kisspeptin Dysregulation

Polycystic ovary syndrome affects 8-13% of reproductive-age women and is characterized by anovulation, hyperandrogenism, and metabolic dysfunction. Hestiantoro et al. (2024) measured the expression of kisspeptin (KISS1), dynorphin (PDYN), neurokinin B, leptin, and neuropeptide Y in 20 women with PCOS and 20 controls.^[3] The KISS1/PDYN ratio was elevated in PCOS women (p = 0.02), driven by reduced dynorphin expression (p < 0.001).

This finding is mechanistically important. In the KNDy neuron circuit, dynorphin provides inhibitory feedback that prevents excessive GnRH pulsatility. When dynorphin is reduced, kisspeptin's excitatory drive is unopposed, potentially explaining the elevated LH pulse frequency that characterizes PCOS. The high KISS1/PDYN ratio could serve as a biomarker for the neuroendocrine component of PCOS, distinct from the metabolic and ovarian markers currently used for diagnosis. This connects to the broader peptide dysregulation in PCOS discussed in the article on peptide hormone dysregulation in PCOS.

Kisspeptin's Dual Role: Reproduction and Metabolism

Sliwowska et al. (2024) reviewed the evidence that kisspeptin regulates both reproduction and metabolism, acting through receptors not only in the hypothalamus but also in brown adipose tissue and the pancreas.^[6] Metabolic conditions including diabetes, obesity, and undernutrition all disrupt kisspeptin signaling, which simultaneously impairs reproductive function. This dual role means that kisspeptin sits at the intersection of two of the body's most fundamental regulatory systems.

The clinical implications are substantial but underexplored. Of clinical kisspeptin studies to date, 85% focus exclusively on reproduction and only 15% address metabolic applications. A single study has attempted to target both simultaneously. Given that conditions like PCOS involve simultaneous reproductive and metabolic dysfunction, a peptide that links both systems represents a therapeutic opportunity that has barely been tested.

Ronnekleiv et al. (2019) detailed how arcuate kisspeptin neurons coordinate reproductive activity with metabolic state, receiving inputs from leptin, insulin, and glucose-sensing neurons to gate reproductive function based on energy availability.^[2] This explains why undernutrition suppresses reproduction (kisspeptin neurons are inhibited by low leptin) and why obesity can either enhance or impair fertility depending on the specific metabolic milieu.

Limitations and What Remains Unknown

The IVF trigger data, while promising, has important limitations. All clinical trials have been conducted by a single research group at one center (Imperial College London). Multi-center replication and Phase 3 trials have not been completed. The optimal dose, timing, and patient selection criteria are still being refined.

Kisspeptin-54's short half-life is both its advantage (preventing OHSS) and its limitation (potentially insufficient LH surge for some patients). The second-dose protocol partly addresses this, but the balance between adequate egg maturation and OHSS prevention may vary between patients in ways that current protocols do not account for.

The sexual function studies (HSDD, limbic brain processing) measured brain activity and self-reported outcomes during acute kisspeptin infusion. Whether repeated kisspeptin administration could produce sustained improvements in sexual function has not been tested. The gap between modulating brain activity during an fMRI scan and treating a chronic condition is substantial.

Long-term safety data do not exist. Kisspeptin has been administered acutely in all published trials. Chronic effects on the HPG axis, potential desensitization of KISS1R, and effects on tissues beyond the hypothalamus remain uncharacterized. The connection between kisspeptin and GnRH signaling means that chronic administration could theoretically downregulate the reproductive axis, similar to what happens with continuous GnRH agonist exposure.

The Bottom Line

Kisspeptin-54 triggers oocyte maturation through the brain's natural GnRH-LH pathway rather than directly activating ovarian receptors like hCG. Phase 2 trials in high-risk IVF patients show 95% maturation rates with no OHSS, dramatically less ovarian swelling and pain than hCG, and a safety profile consistent with kisspeptin's 28-minute half-life. Beyond IVF, kisspeptin modulates sexual brain processing in both men and women and is dysregulated in PCOS. All IVF data comes from a single center, Phase 3 trials are pending, and long-term safety is unknown.

Frequently Asked Questions

What is kisspeptin and how does it trigger ovulation?

Kisspeptin is a hypothalamic neuropeptide that sits at the top of the reproductive hormone cascade. It activates GnRH neurons, which trigger LH release from the pituitary, which stimulates oocyte maturation in the ovary. In IVF, a subcutaneous injection of kisspeptin-54 produces a natural, self-limiting LH surge sufficient to mature eggs for retrieval.^[1] Unlike hCG, this surge resolves within 24 hours.

Is kisspeptin safer than hCG for IVF trigger?

In Phase 2 clinical trials, kisspeptin-54 produced dramatically less ovarian hyperstimulation than hCG in high-risk patients. Ovarian volume increased 5-fold with kisspeptin vs 20-fold with hCG. Abdominal pain occurred in 12% vs 69%, and vomiting in 1% vs 8%. No patient developed moderate or severe OHSS after kisspeptin triggering, though all were selected because they were at high risk for it.^[1]

How effective is kisspeptin at maturing eggs for IVF?

In a Phase 2 trial of 60 high-risk women, kisspeptin-54 triggered oocyte maturation in 95% (57/60) of patients and embryo formation in 90% (54/60). A follow-up trial showed that a second kisspeptin dose 10 hours after the first improved mature oocyte yield. These rates are comparable to traditional hCG triggering, though direct head-to-head comparison trials have not been published.

Is kisspeptin FDA approved for IVF?

No. Kisspeptin-54 is not approved by the FDA or any regulatory agency for IVF or any other clinical use. It has completed Phase 2 clinical trials at Imperial College London, but Phase 3 trials and multi-center replication are required before regulatory approval could be pursued. All published clinical data comes from a single research center in the UK.

Does kisspeptin affect sexual desire?

In controlled clinical trials, kisspeptin-54 modulated sexual brain processing in both men and women. In 32 women with hypoactive sexual desire disorder, kisspeptin increased self-reported feelings of feeling "sexy" and reduced sexual aversion compared to placebo.^[4] In 29 healthy men, it enhanced limbic brain activity specifically in response to sexual stimuli.^[5] Long-term effects have not been studied.

What is kisspeptin's role in PCOS?

In women with PCOS, the ratio of kisspeptin to dynorphin (KISS1/PDYN) is elevated, primarily due to reduced dynorphin expression. This imbalance may explain the excessive GnRH pulsatility and elevated LH that characterize PCOS.^[3] Understanding this peptide imbalance could lead to targeted therapies that address the neuroendocrine root of PCOS rather than just its symptoms.